Earnings calls

Gufic Biosciences Limited concall ledger

Every earnings call for GUFICBIO — management tone, guidance, KPIs and promise tracking, quarter by quarter.

GUFICBIO · 7 transcripts · Healthcare · latest Q4 FY26

Gufic Biosciences Limited has 7 earnings calls on record here, a Healthcare company, most recently Q4 FY26. Each quarter is scored on revenue, margins, guidance delivery and the questions management left unanswered — so the gap between what was promised and what was delivered is easy to read.

Q4 FY26Published 01 Jun 2026Call held 01 Jun 2026

GUFICBIO Q4 FY26 Earnings Call Transcript & Analysis

FY26 Revenue₹940.5 cr+15% YoYFY26 EBITDA₹152.9 cr+10% YoYFY26 EBITDA Margin16.26%FY26 PAT₹63.2 cr−10% YoY

FY26 Revenue ₹940 cr (+15% YoY); FY26 EBITDA ₹153 cr (+10% YoY); FY26 EBITDA Margin 16.26%. Q4 FY26 Revenue grew 22.92% YoY to INR 252 crores, marking the strongest quarter ever.

Read full transcript & analysis

Q3 FY26Published 16 Feb 2026Call held 16 Feb 2026

GUFICBIO Q3 FY26 Earnings Call Transcript & Analysis

Revenue₹231.1 crEBITDA₹37.1 crEBITDA Margin16.05%PAT₹15.6 crPAT Margin6.75%

Revenue ₹231 cr; EBITDA ₹37 cr; EBITDA Margin 16.05%. Q3 FY26 Revenue at INR 231.1 crores, a marginal 0.3% QoQ growth.

Read full transcript & analysis

Q2 FY26Published 17 Nov 2025Call held 17 Nov 2025

GUFICBIO Q2 FY26 Earnings Call Transcript & Analysis

Revenue₹230 crEBITDA₹37.9 crEBITDA Margin16.45%PAT₹14.9 crPAT Margin6.47%

Revenue ₹230 cr; EBITDA ₹38 cr; EBITDA Margin 16.45%. Total revenue for Q2 FY26 was ₹230 crores, a 1.3% QoQ increase from ₹227 crores in Q1 FY26.

Read full transcript & analysis

Q1 FY26Published 14 Aug 2025Call held 14 Aug 2025

GUFICBIO Q1 FY26 Earnings Call Transcript & Analysis

Revenue₹226.9 crEBITDA₹33.2 crEBITDA Margin14.63%PAT₹12.1 crPAT Margin5.33%

Revenue ₹227 cr; EBITDA ₹33 cr; EBITDA Margin 14.63%. Total revenue from operations for Q1 FY26 was INR 226.9 crores, up 10.68% QoQ from INR 205 crores in Q4 FY25.

Read full transcript & analysis

Q4 FY25Published 02 Jun 2025Call held 02 Jun 2025

GUFICBIO Q4 FY25 Earnings Call Transcript & Analysis

Revenue₹205 cr+5% YoYEBITDA₹27 cr−23% YoYEBITDA Margin13.17%PAT₹8 cr−60% YoYPAT Margin3.9%

Revenue (Q4) ₹205 cr (+5% YoY); EBITDA (Q4) ₹27 cr (−23% YoY); EBITDA Margin (Q4) 13.17%. Q4 FY25 Revenue from operations was ₹205 crores, up 5.1% YoY from ₹195 crores in Q4 FY24.

Read full transcript & analysis

Q3 FY25Published 17 Feb 2025Call held 17 Feb 2025

GUFICBIO Q3 FY25 Earnings Call Transcript & Analysis

Revenue₹207.8 cr+3% YoYEBITDA₹35.8 cr−3% YoYEBITDA Margin17.23%PAT₹19.4 cr−13% YoYPBT₹26.3 cr−11% YoY

Revenue (Q3 FY25) ₹208 cr (+3% YoY); EBITDA (Q3 FY25) ₹36 cr (−3% YoY); EBITDA Margin (Q3 FY25) 17.23%. Q3 FY25 total revenue for operations was INR 207.8 crores, compared to INR 201.8 crores in Q3 FY24.

Read full transcript & analysis

Q2 FY25Published 18 Nov 2024Call held 18 Nov 2024

GUFICBIO Q2 FY25 Earnings Call Transcript & Analysis

Revenue₹204.2 cr−5% YoYEBITDA₹38.7 cr−3% YoYEBITDA Margin18.9%PAT₹21.8 cr−6% YoYPAT Margin10.66%

Revenue (Q2 FY25) ₹204 cr (−5% YoY); EBITDA (Q2 FY25) ₹39 cr (−3% YoY); EBITDA Margin (Q2 FY25) 18.9%. Q2 FY25 Revenue: ₹204.2 crores (down 4.98% YoY).

Read full transcript & analysis